Related Experiment Videos
[Acinetobacter, a nosocomial pathogen. Contribution of experimental models].
M L Joly-Guillou1, N Hidri, M Wolff
1Hôpital Louis-Mourier, service de microbiologie, 178, rue des Renouilliers, 92701 Colombes. marie-laure.joly-guillou@lmr.ap-hop-paris.fr
Presse Medicale (Paris, France : 1983)
|May 9, 2002
Summary
Acinetobacter infections, often pneumonia in ventilated patients, are increasingly common and difficult to treat due to multi-drug resistant strains. Sulbactam shows promise for treating these challenging Acinetobacter infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Critical Care Medicine
Context:
- Acinetobacter species are significant nosocomial pathogens, frequently causing outbreaks in intensive care units.
- Acinetobacter infections, primarily pneumonia in mechanically ventilated patients, pose a growing clinical challenge.
Purpose:
- To investigate the virulence of clinical Acinetobacter isolates using a mouse model of systemic infection.
- To evaluate the efficacy of antibiotics, including Sulbactam, in treating Acinetobacter pneumonia in a mouse model.
Summary:
- Clinical Acinetobacter isolates exhibit multi-drug resistance, complicating treatment options.
- Animal models, specifically mouse models, are crucial for understanding Acinetobacter physiopathology, pharmacology, and therapeutic efficacy.
- Sulbactam, used alone or in combination, has demonstrated success in treating Acinetobacter infections.
Impact:
- This research provides insights into Acinetobacter pathogenesis and informs therapeutic strategies for difficult-to-treat infections.
- Highlights the importance of developing effective treatments against multi-drug resistant Acinetobacter strains.
- Emphasizes the utility of animal models in bridging preclinical research and clinical application for Acinetobacter infections.